Diagnostic Pathway Variation: Why Delivery Breaks Before Discovery Does
Even when eligible patients are identified, access to diagnostic‑driven therapies is not consistent.
Across real‑world healthcare systems, variation in the diagnostic pathway continues to limit how those patients move from testing to treatment.
Diagnostic‑driven therapies are advancing rapidly, supported by increasingly precise diagnostics and a growing understanding of disease biology. But in practice, that scientific progress does not translate consistently into patient access.
The gap is not one of discovery - it is one of delivery.
Why Delivery Breaks Before Discovery Does
In theory, diagnostic‑driven therapies should reach all eligible patients through clearly defined testing and treatment pathways. In practice, those pathways are far from consistent.
Testing occurs at different stages of care.
Diagnostic processes vary across laboratories and healthcare systems.
Referral patterns, turnaround times, and reporting quality all influence whether eligible patients ultimately receive the therapy intended for them.
As a result, patient journeys diverge.
Some patients move efficiently from diagnosis to treatment. Others experience delays, incomplete testing, or breakdowns in coordination that limit their access to therapy.
Delivery, not eligibility, determines access
Inconsistent delivery means that eligibility alone does not guarantee access.
Two patients with the same clinical profile may follow entirely different pathways depending on where they are treated and how diagnostics are implemented.
In some settings, testing is aligned to clinical decision‑making and results are acted on quickly. In others, delays or gaps mean that treatment opportunities narrow before action can be taken.
Without visibility, variation remains hidden
Traditional data sources provide insight into outcomes, but not into how pathways function as decisions are being made. They show where therapies are prescribed, but not always:
- where testing is delayed
- where patients are not progressing through the pathway
- or where opportunities to intervene are being missed
As a result, variation remains hidden.
This limits the ability to identify where access is constrained, understand which parts of the pathway are underperforming, and prioritize action where it can have the greatest impact.
Understanding where pathways break
Addressing delivery challenges begins with making variation visible.
This requires decision‑ready intelligence grounded in real‑world diagnostic activity - insight that reflects how patient pathways are actually unfolding in practice.
At Diaceutics, this is enabled through Intelligence Solutions such as DXRX Signal, which identifies real-world diagnostic activity and the HCPs and labs shaping care. Powered by an extensive, lab‑anchored diagnostic data ecosystem, these solutions translate complex data into decision‑ready intelligence that reveals where clinical practice gaps are emerging and where intervention can make a difference.
From variation to focused action
When variation becomes visible, it becomes actionable.
Rather than relying on broad assumptions, biopharma teams can focus on the specific, pathways and clinical behaviors shaping real‑world therapy performance.
In practice, this enables teams to identify where delivery is breaking down, prioritize resources based on real diagnostic activity, and align intervention to where it can still influence outcomes.
This shift- from retrospective reporting to prioritization - allows for more targeted and effective action.
This prioritization is what enables targeted activation through Engagement Solutions - ensuring that the right stakeholders are reached while decisions are still being formed.
Coordinated pathways require coordinated action
Improving access does not depend on changing the science. It depends on improving how that science is delivered in practice.
This requires connecting diagnostic intelligence directly to timely, targeted engagement - ensuring that intervention happens while treatment decisions are still forming.
Through Diaceutics’ Engagement Solutions, this intelligence is activated within the treatment decision window, delivering relevant, expert-led engagement to the HCPs and labs shaping care at the moment it matters most.
When insight and action are aligned:
- engagement becomes more relevant
- decisions are better informed
- and pathways become more consistent
This is not about increasing activity. It is about acting with precision - at the moment it matters most.
Meet our team at ASCO 2026
Talk to our team at ASCO 2026 to discover more about how decision‑ready diagnostic intelligence and timely, targeted engagement can unlock the full potential of your diagnostic-driven therapy. Schedule a meeting Diaceutics at ASCO or Contact Us to to find out more about how our solutions can support your diagnostic‑driven therapy.
